| Attribute |
Value |
| 52 Week Change |
-0.8312236 |
| Address1 |
62 Lygon Street |
| Address2 |
Level 3 |
| All Time High |
50.82 |
| All Time Low |
1.0 |
| Ask |
1.68 |
| Ask Size |
2 |
| Average Analyst Rating |
1.2 - Strong Buy |
| Average Daily Volume10 Day |
62,110 |
| Average Daily Volume3 Month |
87,360 |
| Average Volume |
87,360 |
| Average Volume10Days |
62,110 |
| Beta |
0.86 |
| Bid |
0.9216 |
| Bid Size |
2 |
| Book Value |
1.460697 |
| City |
Carlton |
| Compensation As Of Epoch Date |
1,798,675,200 |
| Country |
Australia |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
1.1999 |
| Current Ratio |
1.16 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
1.27 |
| Day Low |
1.02 |
| Display Name |
Radiopharm Theranostics |
| Dividend Yield |
0.0 |
| Ebitda |
-50,251,072 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-0.216 |
| Enterprise To Revenue |
0.843 |
| Enterprise Value |
10,847,152 |
| Eps Current Year |
-3.23 |
| Eps Forward |
-2.3193984 |
| Eps Trailing Twelve Months |
-3.64 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
61 3 9822 7735 |
| Fifty Day Average |
2.01904 |
| Fifty Day Average Change |
-0.8191401 |
| Fifty Day Average Change Percent |
-0.4057077 |
| Fifty Two Week Change Percent |
-83.12236 |
| Fifty Two Week High |
16.25 |
| Fifty Two Week High Change |
-15.0501 |
| Fifty Two Week High Change Percent |
-0.92616004 |
| Fifty Two Week Low |
1.0 |
| Fifty Two Week Low Change |
0.19990003 |
| Fifty Two Week Low Change Percent |
0.19990003 |
| Fifty Two Week Range |
1.0 - 16.25 |
| Financial Currency |
AUD |
| First Trade Date Milliseconds |
1,733,409,000,000 |
| Float Shares |
11,964,263 |
| Forward Eps |
-2.3193984 |
| Forward P E |
-0.51733243 |
| Free Cashflow |
-31,142,938 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
14 |
| Fullday Change |
0.034999967 |
| Fullday Change Percent |
3.0836976 |
| Fullday Price |
1.1999 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
-2.66888 |
| Gross Profits |
-34,335,448 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.0 |
| Held Percent Institutions |
0.0073900004 |
| Implied Shares Outstanding |
14,591,832 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,024-11-27 |
| Language |
en-US |
| Last Fiscal Year End |
1,782,777,600 |
| Long Business Summary |
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia. |
| Long Name |
Radiopharm Theranostics Limited |
| Market |
us_market |
| Market Cap |
17,508,740 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_1685428878 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-56,950,496 |
| Next Fiscal Year End |
1,814,313,600 |
| Non Diluted Market Cap |
21,813,115 |
| Number Of Analyst Opinions |
6 |
| Open |
1.07 |
| Operating Cashflow |
-52,782,840 |
| Operating Margins |
-4.00348 |
| Phone |
61 3 9824 5254 |
| Previous Close |
1.135 |
| Price Eps Current Year |
-0.37148607 |
| Price Hint |
4 |
| Price To Book |
0.82145715 |
| Price To Sales Trailing12 Months |
1.3609458 |
| Profit Margins |
0.0 |
| Quick Ratio |
1.142 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.2 |
| Region |
US |
| Regular Market Change |
0.06490004 |
| Regular Market Change Percent |
5.7180653 |
| Regular Market Day High |
1.27 |
| Regular Market Day Low |
1.02 |
| Regular Market Day Range |
1.02 - 1.27 |
| Regular Market Open |
1.07 |
| Regular Market Previous Close |
1.135 |
| Regular Market Price |
1.1999 |
| Regular Market Time |
1,791,921,600 |
| Regular Market Volume |
143,212 |
| Return On Assets |
-0.45150003 |
| Return On Equity |
-1.74707 |
| Revenue Growth |
-0.369 |
| Revenue Per Share |
1.2 |
| Sand P52 Week Change |
0.17004645 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
14,591,832 |
| Shares Percent Shares Out |
0.0023999999 |
| Shares Short |
34,322 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
30,426 |
| Short Name |
Radiopharm Theranostics Limited |
| Short Percent Of Float |
0.0026 |
| Short Ratio |
0.67 |
| Source Interval |
15 |
| State |
VIC |
| Symbol |
RADX |
| Target High Price |
30.016716 |
| Target Low Price |
12.442882 |
| Target Mean Price |
16.994516 |
| Target Median Price |
15.30684 |
| Total Cash |
4,138,074 |
| Total Cash Per Share |
0.286 |
| Total Debt |
0 |
| Total Revenue |
12,865,126 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-3.64 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
3.942015 |
| Two Hundred Day Average Change |
-2.742115 |
| Two Hundred Day Average Change Percent |
-0.69561255 |
| Type Disp |
Equity |
| Volume |
143,212 |
| Website |
https://www.radiopharmtheranostics.com |
| Zip |
3,053 |